Evidence map›Paper›PMID 40985497›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2025

Investigation of the Impact of Tryptophan-Metabolizing Enzymes and Kynurenic Acid on Antibody-Mediated Glomerulonephritis.

Ryosuke Umeda, Yoshimasa Ito, Shun Minatoguchi, Shigehisa Koide, Kazuo Takahashi, Hiroki Hayashi, Midori Hasegawa, Yukio Yuzawa, Yasuko Yamamoto, Kuniaki Saito and 1 more

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Investigation of the Impact of Tryptophan-Metabolizing Enzymes and Kynurenic Acid on Antibody-Mediated Glomerulonephritis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ryosuke UmedaDepartment of Nephrology, Fujita Health University School of Medicine, Toyoake City, Aichi, Japan.ORCID https://orcid.org/0000-0002-4607-2136
Yoshimasa ItoDepartment of Nephrology, Fujita Health University School of Medicine, Toyoake City, Aichi, Japan.
Shun MinatoguchiDepartment of Nephrology, Fujita Health University School of Medicine, Toyoake City, Aichi, Japan.
Shigehisa KoideDepartment of Nephrology, Fujita Health University School of Medicine, Toyoake City, Aichi, Japan.
Kazuo TakahashiDepartment of Nephrology, Fujita Health University School of Medicine, Toyoake City, Aichi, Japan.
Hiroki HayashiDepartment of Nephrology, Fujita Health University School of Medicine, Toyoake City, Aichi, Japan.
Midori HasegawaDepartment of Nephrology, Fujita Health University School of Medicine, Toyoake City, Aichi, Japan.
Yukio YuzawaDepartment of Nephrology, Fujita Health University School of Medicine, Toyoake City, Aichi, Japan.
Yasuko YamamotoDepartment of Advanced Diagnostic System Development, Fujita Health University School of Health Sciences, Toyoake City, Aichi, Japan.
Kuniaki SaitoDepartment of Advanced Diagnostic System Development, Fujita Health University School of Health Sciences, Toyoake City, Aichi, Japan.
Naotake TsuboiDepartment of Nephrology, Fujita Health University School of Medicine, Toyoake City, Aichi, Japan.ORCID https://orcid.org/0000-0003-0760-845X

Funding

Aichi Kidney FoundationFujita Health UniversityGlaxoSmithKline Japan (GSK)Japan Society for the Promotion of Science London (JSPS) C,#22K08344
6 · The paper itself

Abstract

Tryptophan (TRP) metabolism through the kynurenine pathway generates multiple biologically active metabolites with diverse immunomodulatory effects, but their roles in glomerulonephritis (GN), particularly in innate immunity, remain poorly understood. Using a nephrotoxic serum-induced GN (NTS-GN) model, we first analyzed mice deficient in key TRP-metabolizing enzymes of the kynurenine pathway: Indoleamine 2,3-dioxygenase 1 and 2 (IDO1 and IDO2), and kynurenine 3-monooxygenase (KMO), and found that Ido1-deficient mice exhibited exacerbated kidney injury and glomerular neutrophil infiltration, whereas Ido2 deficiency had no significant impact. In contrast, Kmo-deficient mice showed reduced crescent formation. Unexpectedly, the concentration of kynurenic acid (KYNA), a downstream metabolite of IDO1, was elevated in the kidney cortex of Ido1-deficient mice. Exogenous KYNA administration improved survival, ameliorated renal injury, and reduced neutrophil infiltration in Ido1-deficient mice, indicating its protective effect against antibody-mediated injury. Moreover, KYNA suppressed immune complex-mediated neutrophil spreading, attenuated FcγR-dependent Syk phosphorylation, and reduced VEGF secretion in vitro. Our results position KYNA as a key modulator of neutrophil-driven inflammation in antibody-mediated GN. This study uncovers distinct roles for kynurenine pathway enzymes and highlights the TRP-KYNA pathway as a promising immunometabolic target for controlling innate immune responses in GN.

Indexed as

GlomerulonephritisIndoleamine-Pyrrole 2,3,-DioxygenaseKynurenic AcidKynurenine 3-MonooxygenaseTryptophanAnimalsKynurenineMaleMiceMice, Inbred C57BLMice, KnockoutIDO1 protein, mouseIDO2 protein, mouseIndoleamine-Pyrrole 2,3,-DioxygenaseKynurenic AcidKynurenineKynurenine 3-MonooxygenaseTryptophanglomerulonephritisIndoleamine 2,3‐dioxygenasekynurenic acidneutrophilsRRID:AB_2337118RRID:IMSR_JAX:005867RRID:MGI:2159965RRID:MGI:3028467RRID:MGI:5759308tryptophan

Identifiers

PMID40985497
PMCPMC12455905

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.